Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19

Current formulations and dose regimens of hydroxychloroquine (HCQ) put patients at risk of harm. An analysis of clinical trials registered on ClinicalTrials.gov revealed that this may continue as many studies combine HCQ with agents that prolong the QT interval. Further, almost all of the trials reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Kavanagh, Oisín, Marie Healy, Anne, Dayton, Francis, Robinson, Shane, O'Reilly, Niall J., Mahoney, Brian, Arthur, Aisling, Walker, Gavin, Farragher, John P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Letter to Editors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361049/
https://www.ncbi.nlm.nih.gov/pubmed/33017904
http://dx.doi.org/10.1016/j.mehy.2020.110110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361049/
https://www.ncbi.nlm.nih.gov/pubmed/33017904
http://dx.doi.org/10.1016/j.mehy.2020.110110

Ejemplares similares